Pediatric Optimal Tuberculosis Treatment Evaluation and Reassessment (POTTER)
Status
Conditions
Details and patient eligibility
About
The treatment of tuberculosis disease in children benefits from clear and up-to-date recommendations from the World Health organization. The research issues supported by the WHO mainly concern tuberculosis treatment implementation in areas of high incidence and low economic level. Pediatric cohorts in countries with high economic levels are rare, making it impossible to quantify and describe deviations from optimal recommendations. The French recommendations are mainly focused on screening cases of tuberculosis, without specific guidelines for care organization and recent practice evaluation.
The retrospective study of patients followed by the pediatric infectious disease team of the Hospices Civils de Lyon (HCL) would allow to quantify treatment successes and failures, and to describe these failures in a French pediatric tertiary care center. This retrospective analysis is part of an evolution of the pediatric infectious diseases' activity of HCL in 2024: structuring of the service with a full-time practitioner, establishment of multi-professional care with the involvement of psychologists and clinical pharmacists. This retrospective study will help to understand the causes of failure in French tertiary pediatric centers and to describe the expected benefits of a structured and multi-professional care to improve the treatment of pediatric tuberculosis diseases in France.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria :
- Patients under 18 years old, with tuberculosis disease confirmed from patient's clinical file
Exclusion Criteria :
- Tuberculosis disease ruled out from patient's clinical file
- Parental opposition or patient opposition (if over 18 years old)
Trial design
150 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal